730-P: Basal Insulin Regimen vs. Twice-Daily Premix Insulin Regimen after Short-Term Intensive Insulin Therapy (SIT) in Patients with Type 2 Diabetes (T2D): A Multicenter, Open-Label Randomized Controlled Trial

Intensive Insulin Therapy ◽

Basal Insulin ◽

Controlled Trial ◽

Insulin Regimen ◽

Short Term ◽

Open Label ◽

Effects of Sodium Glucose Co-Transporter 2 Inhibitor Canagliflozin in Patients with Type 2 Diabetes and Chronic Heart Failure (CANDLE): An Open-Label, Randomized Controlled Trial

SSRN Electronic Journal ◽

10.2139/ssrn.3343659 ◽

2019 ◽

Author(s):

Atsushi Tanaka ◽

Itaru Hisauchi ◽

Isao Taguchi ◽

Akira Sezai ◽

Shigeru Toyoda ◽

...

Keyword(s):

Heart Failure ◽

Type 2 Diabetes ◽

Chronic Heart Failure ◽

Controlled Trial ◽

Open Label ◽

Advancing therapy with iGlarLixi versus premix BIAsp 30 in basal insulin‐treated type 2 diabetes: Design and baseline characteristics of the SoliMix randomized controlled trial

10.1111/dom.14354 ◽

2021 ◽

Cited By ~ 1

Author(s):

Rory J. McCrimmon ◽

Saud Al Sifri ◽

Rifat Emral ◽

Viswanathan Mohan ◽

Leobardo Sauque‐Reyna ◽

...

Keyword(s):

Type 2 Diabetes ◽

Basal Insulin ◽

Controlled Trial ◽

Randomized Controlled ◽

Baseline Characteristics

RESVERATROL SUPPLEMENTATION IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: A PROSPECTIVE, OPEN LABEL, RANDOMIZED CONTROLLED TRIAL

International Research Journal of Pharmacy ◽

10.7897/2230-8407.04849 ◽

2013 ◽

Vol 4 (8) ◽

pp. 245-249 ◽

Cited By ~ 20

Author(s):

Jayesh Kumar Bhatt ◽

Moola Joghee Nanjan

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Controlled Trial ◽

Open Label ◽

Efficacy of two telemonitoring systems to improve glycaemic control during basal insulin initiation in patients with type 2 diabetes: The TeleDiab‐2 randomized controlled trial

10.1111/dom.13806 ◽

2019 ◽

Vol 21 (10) ◽

pp. 2327-2332 ◽

Cited By ~ 2

Author(s):

Sylvia Franc ◽

Michael Joubert ◽

Ahmed Daoudi ◽

Cédric Fagour ◽

Pierre‐Yves Benhamou ◽

...

Keyword(s):

Type 2 Diabetes ◽

Glycaemic Control ◽

Basal Insulin ◽

Controlled Trial ◽

Insulin Initiation ◽

New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Oral Agents and Basal Insulin: Glucose Control and Hypoglycemia in a 6-Month Randomized Controlled Trial (EDITION 2)

Diabetes Care ◽

10.2337/dc14-0990 ◽

2014 ◽

Vol 37 (12) ◽

pp. 3235-3243 ◽

Cited By ~ 169

Author(s):

Hannele Yki-Järvinen ◽

Richard Bergenstal ◽

Monika Ziemen ◽

Marek Wardecki ◽

Isabel Muehlen-Bartmer ◽

...

Keyword(s):

Type 2 Diabetes ◽

Insulin Glargine ◽

Glucose Control ◽

Basal Insulin ◽

Controlled Trial ◽

Randomized Controlled ◽

Oral Agents

Efficacy and Safety of Liraglutide 3.0 mg in Individuals With Overweight or Obesity and Type 2 Diabetes Treated With Basal Insulin: The SCALE Insulin Randomized Controlled Trial

Diabetes Care ◽

10.2337/dc19-1745 ◽

2020 ◽

Vol 43 (5) ◽

pp. 1085-1093 ◽

Cited By ~ 7

Author(s):

W. Timothy Garvey ◽

Andreas L. Birkenfeld ◽

Dror Dicker ◽

Geltrude Mingrone ◽

Sue D. Pedersen ◽

...

Keyword(s):

Type 2 Diabetes ◽

Basal Insulin ◽

Controlled Trial ◽

Efficacy And Safety ◽

Randomized Controlled ◽

Overweight Or Obesity

A randomized controlled trial of liraglutide versus insulin detemir plus sitagliptin: Effective switch from intensive insulin therapy to the once-daily injection in patients with well-controlled type 2 diabetes

The Journal of Clinical Pharmacology ◽

10.1002/jcph.483 ◽

2015 ◽

Vol 55 (7) ◽

pp. 831-838 ◽

Cited By ~ 2

Author(s):

Yuichiro Inoue ◽

Akinobu Nakamura ◽

Yoshinobu Kondo ◽

Kumiko Hamano ◽

Shinobu Satoh ◽

...

Keyword(s):

Type 2 Diabetes ◽

Insulin Therapy ◽

Intensive Insulin Therapy ◽

Insulin Detemir ◽

Controlled Trial ◽

Daily Injection ◽

Once Daily ◽

New insulin glargine 300 U/ml versus glargine 100 U/ml in Japanese people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 2)

10.1111/dom.12618 ◽

2016 ◽

Vol 18 (4) ◽

pp. 366-374 ◽

Cited By ~ 67

Author(s):

Y. Terauchi ◽

M. Koyama ◽

X. Cheng ◽

Y. Takahashi ◽

M. C. Riddle ◽

...

Keyword(s):

Type 2 Diabetes ◽

Insulin Glargine ◽

Glucose Control ◽

Basal Insulin ◽

Controlled Trial ◽

Japanese People ◽

Randomized Controlled ◽

Antihyperglycaemic Drugs

Flash Glucose-Sensing Technology as a Replacement for Blood Glucose Monitoring for the Management of Insulin-Treated Type 2 Diabetes: a Multicenter, Open-Label Randomized Controlled Trial

Diabetes Therapy ◽

10.1007/s13300-016-0223-6 ◽

2016 ◽

Vol 8 (1) ◽

pp. 55-73 ◽

Cited By ~ 191

Author(s):

Thomas Haak ◽

Hélène Hanaire ◽

Ramzi Ajjan ◽

Norbert Hermanns ◽

Jean-Pierre Riveline ◽

...

Keyword(s):

Type 2 Diabetes ◽

Controlled Trial ◽

Glucose Monitoring ◽

Glucose Sensing ◽

Blood Glucose Monitoring ◽

Open Label ◽

Randomized Controlled ◽

Sensing Technology

Higher versus standard starting dose of insulin glargine 100 U/mL in overweight or obese Chinese patients with type 2 diabetes: Results of a multicentre, open‐label, randomized controlled trial (BEYOND VII)

10.1111/dom.13967 ◽

2020 ◽

Vol 22 (5) ◽

pp. 838-846

Author(s):

Linong Ji ◽

Hailong Wan ◽

Binhong Wen ◽

Xueying Wang ◽

Junfen Wang ◽

...

Keyword(s):

Type 2 Diabetes ◽

Insulin Glargine ◽

Controlled Trial ◽

Chinese Patients ◽

Open Label ◽

Randomized Controlled ◽

Starting Dose